You are here: Industry Insights > Lung Cancer

News List

AI could spot lung cancer before radiologists pharmatimes
May 21, 2019
Artificial Intelligence (AI) ‘deep learning’ has been found to detect malignant lung nodules on low-dose chest computed tomography (LDCT) scans sooner than radiologists.
AstraZeneca tees up PGA champ Day to push biomarker testing in lung cancer fiercepharma
May 09, 2019
AstraZeneca and pro golfer Jason Day are on a mission to encourage biomarker testing for lung cancer. For Day, the awareness campaign is personal—he found out two years ago that his mother had stage IV lung cancer.
J&J's quest to detect lung cancer before it emerges fiercebiotech
April 28, 2019
Smoking causes injuries in the respiratory tract that can evolve into lung cancer. Researchers from Johnson & Johnson Innovation and Boston University wondered whether it might be possible to prevent lung lesions from becoming cancerous ...
FDA expands Keytruda label to include stage 3 and 4 non-small cell lung cancer pharmafile
April 23, 2019
MSD has revealed that its anti-PD-1 therapy Keytruda (pembrolizumab) has received expanded indication from the FDA to include the first-line treatment of stage 3 or metastatic non-small cell lung cancer (NSCLC).
SK Biopharmaceuticals and twoXAR Sign Collaboration Agreement to Discover and Develop First-In-Class Treatments for Non-Small Cell Lung Cancer pharmafocusasia
April 19, 2019
SK Biopharmaceuticals and twoXAR Sign Collaboration Agreement to Discover and Develop First-In-Class Treatments for Non-Small Cell Lung Cancer
AZ finds lack of lung cancer info available for patients pharmatimes
April 16, 2019
New AstraZeneca research has shown significant gaps in online sources of information for lung cancer patients.
VolitionRx extends clinical trial programme in lung cancer biospectrumasia
April 08, 2019
VolitionRx Limited has announced that it has added to its extensive clinical trial program with the execution of ……
BMS, clinging to Opdivo's lung cancer share, highlights long-term data fiercepharma
April 04, 2019
After a hard blow to its hopes in previously untreated lung cancer, Bristol-Myers Squibb is clinging to its share of the second-line market.
Blueprint Medicines Announces Accelerated Regulatory Submission Plans and Recent Clinical Progress firstwordpharma
March 28, 2019
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced plans to expedite development of avapritinib, BLU-667 and BLU-782 based on recent c
FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer worldpharmanews
March 21, 2019
Roche announced that FDA approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page